drugset
drugset / Trial / NCT05634525

Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients

NCT05634525 ↗

Phase 1 Withdrawn M.D. Anderson Cancer Center Mirati Therapeutics Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

To learn if the investigational study drug, adagrasib (also called MRTX849), can help to control pancreatic cancer that has a KRAS G12 mutation. The safety and possible effects of adagrasib will also be studied.

Timeline

Start
2023-05-03
Primary completion
2025-07-21
Completion
2025-07-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Adagrasib Small molecule — Oral

Indications

malignant pancreatic neoplasm